The Horizon 2020 Framework Programme for Research and Innovation was launched by the European Commission in January 2014, with a budget of more than EUR 77 billion available over 7 years (2014–2020). The Programme was designed around three pillars:
- Excellent Science
- Industrial Leadership
- Tackling Societal Challenges.
Horizon 2020 utilised supported research and innovation through a number of mechanisms and instruments, including collaboration-based Actions such as Research & Innovation Actions (RIA) and Innovative Training Networks (ITNs), alongside single beneficiary grants such as the Marie-SklodowskaCurie Actions (MSCA), European Research Council (ERC) and SME Instrument actions. Horizon 2020 also contributed funding to existing to the Joint Programming Initiative on Neurodegenerative Diseases Research (JPND).
Under pillar 3, a number of "societal challenges" were identified, with the Societal Challenge 1 (SC1) being "health and wellbeing". SC1 had a budget of EUR 7.4 billion across the duration of the Horizon 2020 Programme.
The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking, was partially funded through Horizon Europe, with EUR 1.63 billion of the EUR 3.27 billion IMI2 budget was sourced this way, with the remainder largely funded by members of European Federation of Pharmaceutical Industries and Associations (EFPIA).
In total, as part of the Horizon 2020 Europe The total funding for all dementia projects amounted to around EUR 573,633,790.28 of which EUR 445,623,027.76 was contributed by the Horizon 2020 Framework Programme.
Further information on the Horizon 2020 Programme is available at: https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en